Pharvaris Phase 3 Study Results Published in The Lancet Medical Journal

Key Facts

1Pharvaris announced the publication of Phase 3 RAPIDe-3 study results for deucrictibant in The Lancet medical journal.

Pharvaris announced the publication of Phase 3 RAPIDe-3 study results for deucrictibant in The Lancet medical journal. The company stated in a release via GlobeNewswire that the data supports the use of the oral drug for the on-demand treatment of hereditary angioedema (HAE) attacks.

PHVS closed at $31.68 on October 7, 2026, with the stock trading between a session low of $30.58 and a high of $32.32. The peer-reviewed publication validates the clinical profile of deucrictibant as the company continues its progress toward regulatory approval.